Free morning briefing · 07:30 weekdays
The RNS that moves prices, in your inbox before the open.
AI-ranked movers and high-impact RNS across the FTSE 100, 250, SmallCap and AIM — one short email, every market day.
Get the briefing
POLB

Poolbeg Pharma PLC

POLBLSEUnited KingdomHealthcareBiotechnologyAIM

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of…more

P/B6.97x
£59.01M
Market Cap
EV: £52.78M
MOM9
QUAL—
VAL—
RSK4
POLB
£59.01M
Market Cap · EV £52.78M

Poolbeg Pharma PLC

MOM9
QUAL—
VAL—
RSK4

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of…more

Latest RNS from Poolbeg Pharma PLC

Analyst consensus: Buy

As of 22 Sept 2026, 1 analyst rate Poolbeg Pharma PLC a Buy, with 100% buy ratings and a mean price target of 19p (range 19p–19p), +114% vs the current price.

Strong buy: 0Buy: 1Hold: 0Sell: 0Strong sell: 0

Full analyst history →

More Healthcare companies